Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103105 | 0.91 | CCR4 (0.63) | CCR4CCR5 | |
| SCHEMBL5105666 | 0.89 | CCR4 (0.82) | CCR4CCR5 | |
| SCHEMBL5103307 | 0.89 | CCR4 (0.78) | CCR4CCR5 | |
| SCHEMBL5106594 | 0.87 | CCR4 (0.64) | CCR4CCR5 | |
| SCHEMBL5105223 | 0.84 | CCR4 (1.00) | CCR4CCR5 | |
| SCHEMBL5103322 | 0.81 | CCR5 (0.71) | CCR4CCR5 | |
| SCHEMBL6182958 | 0.80 | CCR4 (0.74) | CCR4CCR5 | |
| SCHEMBL5111482 | 0.78 | CCR4 (0.76) | CCR4CCR5 | |
| SCHEMBL5098574 | 0.77 | CCR4 (0.70) | CCR4CCR5 | |
| SCHEMBL1732825 | 0.76 | CCR4 (0.77) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | claimed |
| EP-1458715-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | claimed |
| US-20050075346-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | claimed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1458715-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050075346-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458715-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051870-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075346-A1 | Novel compounds | CCL11, CCL2, CCL5 | CCR4 22/4885CCR5 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.